{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:48:56Z","timestamp":1786373336941,"version":"build-2736575974"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","funder":[{"name":"U.S. Department of Veterans Affairs Cooperative Studies Program","award":["CSP 578"],"award-info":[{"award-number":["CSP 578"]}]},{"name":"National Health and Medical Research Council of Australia","award":["APP1011387"],"award-info":[{"award-number":["APP1011387"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>Contrast-associated AKI may result in higher morbidity and mortality. Intravenous fluid administration remains the mainstay for prevention. There is a lack of consensus on the optimal administration strategy. We studied the association of periprocedure fluid administration with contrast-associated AKI, defined as an increase in serum creatinine of at least 25% or 0.5 mg\/dl from baseline at 3\u20135 days after angiography, and 90-day need for dialysis, death, or a 50% increase in serum creatinine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, setting, participants, &amp; measurements<\/jats:title>\n                    <jats:p>We conducted a secondary analysis of 4671 PRESERVE participants who underwent angiographic procedures. Although fluid type was randomized, strategy of administration was at the discretion of the clinician. We divided the study cohort into quartiles by total fluid volume. We performed multivariable logistic regression, adjusting for clinically important covariates. We tested for the interaction between fluid volume and duration of fluid administration, categorized as &lt;6 or \u22656 hours.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The mean (SD) age was 70 (8) years, 94% of participants were male, and median (interquartile range) eGFR was 60 (41\u201360) ml\/min per 1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      . The range of fluid administered was 89\u2013882 ml in quartile 1 and 1258\u20132790 ml in quartile 4. Compared with the highest quartile (quartile 4) of fluid volume, we found a significantly higher risk of the primary outcome in quartile 1 (adjusted odds ratio, 1.58; 95% confidence interval, 1.06 to 2.38) but not in quartiles 2 and 3 compared with quartile 4. There was no difference in the incidence of contrast-associated AKI across the quartiles. The interaction between volume and duration was not significant for any of the outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We found that administration of a total volume of 1000 ml, starting at least 1 hour before contrast injection and continuing postcontrast for a total of 6 hours, is associated with a similar risk of adverse outcomes as larger volumes of intravenous fluids administered for periods &gt;6 hours. Mean fluid volumes &lt;964 ml may be associated with a higher risk for the primary outcome, although residual confounding cannot be excluded.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2215\/cjn.02160222","type":"journal-article","created":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T22:35:17Z","timestamp":1661466917000},"page":"1446-1456","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["The Relationship between Rate and Volume of Intravenous Fluid Administration and Kidney Outcomes after Angiography"],"prefix":"10.2215","volume":"17","clinical-trial-number":[{"clinical-trial-number":"nct01467466","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3182-7225","authenticated-orcid":false,"given":"Qandeel H.","family":"Soomro","sequence":"first","affiliation":[{"name":"New York University Grossman School of Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia T.","family":"Anand","sequence":"additional","affiliation":[{"name":"VA Boston Health Care System Massachusetts Veterans Epidemiology Research and Information Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D.","family":"Weisbord","sequence":"additional","affiliation":[{"name":"VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania"},{"name":"University of Pittsburgh, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin P.","family":"Gallagher","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, Newtown, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan E.","family":"Ferguson","sequence":"additional","affiliation":[{"name":"VA Boston Health Care System Massachusetts Veterans Epidemiology Research and Information Center, Boston, Massachusetts"},{"name":"VA Cooperative Studies Program Coordinating Center, Boston, Massachusetts"},{"name":"Boston University School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7334-5400","authenticated-orcid":false,"given":"Paul M.","family":"Palevsky","sequence":"additional","affiliation":[{"name":"VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania"},{"name":"University of Pittsburgh, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital Heart and Vascular Center, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9051-7385","authenticated-orcid":false,"given":"Chirag R.","family":"Parikh","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James S.","family":"Kaufman","sequence":"additional","affiliation":[{"name":"New York University Grossman School of Medicine, New York, New York"},{"name":"Renal Section, VA New York Harbor Healthcare Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,10]]},"reference":[{"key":"B1-20241015","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1161\/01.CIR.0000016043.87291.33","article-title":"Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention","volume":"105","author":"Rihal","year":"2002","journal-title":"Circulation"},{"key":"B2-20241015","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.ccc.2015.06.008","article-title":"Contrast-associated acute kidney injury","volume":"31","author":"Weisbord","year":"2015","journal-title":"Crit Care Clin"},{"key":"B3-20241015","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s40620-018-0498-y","article-title":"Contrast medium induced acute kidney injury: A narrative review","volume":"31","author":"Pistolesi","year":"2018","journal-title":"J Nephrol"},{"key":"B4-20241015","doi-asserted-by":"crossref","first-page":"i2","DOI":"10.1093\/ndt\/gfh1066","article-title":"Renal haemodynamic alterations in contrast medium-induced nephropathy and the benefit of hydration","volume":"20","author":"Persson","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"B5-20241015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ki.1990.1","article-title":"Renal medullary circulation: Hormonal control","volume":"37","author":"Chou","year":"1990","journal-title":"Kidney Int"},{"key":"B6-20241015","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1710933","article-title":"Outcomes after angiography with sodium bicarbonate and acetylcysteine","volume":"378","author":"Weisbord","year":"2018","journal-title":"N Engl J Med"},{"key":"B7-20241015","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.2215\/CJN.11161012","article-title":"Prevention of contrast-induced AKI: A review of published trials and the design of the prevention of serious adverse events following angiography (PRESERVE) trial","volume":"8","author":"Weisbord","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"B8-20241015","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1016\/j.jcin.2018.07.044","article-title":"Strategies to reduce acute kidney injury and improve clinical outcomes following percutaneous coronary intervention: A subgroup analysis of the PRESERVE Trial","volume":"11","author":"Garcia","year":"2018","journal-title":"JACC Cardiovasc Interv"},{"key":"B9-20241015","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/14779072.2020.1724537","article-title":"Intravenous fluids for the prevention of contrast-induced nephropathy in patients undergoing coronary angiography and cardiac catheterization","volume":"18","author":"Hong","year":"2020","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"B10-20241015","first-page":"385","article-title":"Hydration: Intravenous and oral: Approaches, principals, and differing regimens: Is it what goes in or what comes out that is important?","volume":"9","author":"Solomon","year":"2020","journal-title":"Interv Cardiol Clin"},{"key":"B11-20241015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5414\/CNP62001","article-title":"What is the best hydration regimen to prevent contrast media-induced nephrotoxicity?","volume":"62","author":"Bader","year":"2004","journal-title":"Clin Nephrol"},{"key":"B12-20241015","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1161\/CIRCULATIONAHA.106.687152","article-title":"Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): A randomized comparison of 3 preventive strategies","volume":"115","author":"Briguori","year":"2007","journal-title":"Circulation"},{"key":"B13-20241015","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.jacc.2021.09.006","article-title":"2021 ACC\/AHA\/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Lawton","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"B14-20241015","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1016\/S0140-6736(14)60689-9","article-title":"Haemodynamic-guided fluid administration for the prevention of contrast-induced acute kidney injury: The POSEIDON randomised controlled trial","volume":"383","author":"Brar","year":"2014","journal-title":"Lancet"},{"key":"B15-20241015","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jcin.2011.08.017","article-title":"Prevention of contrast nephropathy by furosemide with matched hydration: The MYTHOS (Induced Diuresis With Matched Hydration Compared to Standard Hydration for Contrast Induced Nephropathy Prevention) trial","volume":"5","author":"Marenzi","year":"2012","journal-title":"JACC Cardiovasc Interv"},{"key":"B16-20241015","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/ccd.28991","article-title":"SCAI position statement on the performance of percutaneous coronary intervention in ambulatory surgical centers","volume":"96","author":"Box","year":"2020","journal-title":"Catheter Cardiovasc Interv"},{"key":"B17-20241015","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1007\/s00330-017-5247-4","article-title":"Post-contrast acute kidney injury. Part 2: Risk stratification, role of hydration and other prophylactic measures, patients taking metformin and chronic dialysis patients: Recommendations for updated ESUR Contrast Medium Safety Committee guidelines","volume":"28","author":"van der Molen","year":"2018","journal-title":"Eur Radiol"},{"key":"B18-20241015","doi-asserted-by":"crossref","first-page":"e003171","DOI":"10.1161\/JAHA.115.003171","article-title":"Excessively high hydration volume may not be associated with decreased risk of contrast-induced acute kidney injury after percutaneous coronary intervention in patients with renal insufficiency","volume":"5","author":"Liu","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"B19-20241015","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1536\/ihj.17-066","article-title":"Safe hydration to prevent contrast-induced acute kidney injury and worsening heart failure in patients with renal insufficiency and heart failure undergoing coronary angiography or percutaneous coronary intervention","volume":"60","author":"Bei","year":"2019","journal-title":"Int Heart J"},{"key":"B20-20241015","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1161\/CIRCINTERVENTIONS.111.961391","article-title":"Effects of hydration in contrast-induced acute kidney injury after primary angioplasty: A randomized, controlled trial","volume":"4","author":"Maioli","year":"2011","journal-title":"Circ Cardiovasc Interv"},{"key":"B22-20241015","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2215\/CJN.03520807","article-title":"Urinary biomarkers for acute kidney injury: Perspectives on translation","volume":"3","author":"Coca","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"B23-20241015","doi-asserted-by":"crossref","first-page":"e021342","DOI":"10.1161\/JAHA.121.021342","article-title":"Tailored versus standard hydration to prevent acute kidney injury after percutaneous coronary intervention: Network meta-analysis","volume":"10","author":"Moroni","year":"2021","journal-title":"J Am Heart Assoc"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.02160222","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:44:57Z","timestamp":1786369497000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.02160222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.02160222","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"2022-02-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}